Last reviewed · How we verify
NCT06587568
Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases
NA trial testing Mobile chat messaging in Chronic Liver Disease in 106 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2025
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 2 October 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Mobile chat messaging
- Screening, brief intervention and referral to treatment
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
Sponsor
The University of Hong Kong
Who can join
18 and older, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases. Specific objectives include: 1. To assess whether the eligibility criteria were too restrictive by estimating the eligibility rate 2. To assess how many eligible CLD patients accepted the invitation to participate in the trial 3. To assess the participant retention rate through 6 months after treatment initiation 4. To assess the intervention acceptability in terms of participants' engagement with and rating of the chat messaging intervention. 5. To assess the safety of the intervention 6. To estimate the intervention effect on alcohol use outcomes and liver functions 7. To synthesise data to inform the sample size calculation in the future definitive trial 8. To explore the participants' perception and experiences in the chat-based intervention
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06587568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mobile chat messaging
Trials testing the same drug.
- NCT07375459 — Community-based Mobile-assisted Brief Intervention for Smoking Cessation · NA · recruiting
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
- NCT07191886 — Measuring Patient Reported Needs in Outpatient Liver Disease Management · recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06587568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing